ReviewOral oncology2021
Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
Review in Oral oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Integrating RNA-seq and Single-Cell RNA-seq to Uncover Transcriptional Signature of Fibroblasts in Oral Squamous Cell Carcinoma.Biochemical genetics · 2026Article
- Review
- Cancer stem cell mechanisms and targeted therapeutic strategies in head and neck squamous cell carcinoma.Cancer letters · 2025Review
- Immune Evasion in Head and Neck Squamous Cell Carcinoma: Roles of Cancer-Associated Fibroblasts, Immune Checkpoints, andCancers · 2025Review
- Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer.Journal of biomedical science · 2025Article
- Tumor microenvironment governs the prognostic landscape of immunotherapy for head and neck squamous cell carcinoma: A computational model-guided analysis.PLoS computational biology · 2025Article
- Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy.International journal of nanomedicine · 2025Review
- A novel mast cell marker gene-related prognostic signature to predict prognosis and reveal the immune landscape in head and neck squamous cell carcinoma.Frontiers in immunology · 2025Article
- Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics.Journal of nanobiotechnology · 2024Review
- Article
- Exploring the Role and Prognostic Value of TMEM208 in Head and Neck Squamous Cell Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- An angiogenesis-associated gene-based signature predicting prognosis and immunotherapy efficacy of head and neck squamous cell carcinoma patients.Journal of cancer research and clinical oncology · 2024Article
- Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma.Discover oncology · 2024Review
- Cytotoxic response of tumor-infiltrating lymphocytes of head and neck cancer slice cultures under mitochondrial dysfunction.Frontiers in oncology · 2024Article
- Article
- Review
- Review
- Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma.Frontiers in medicine · 2023Review
- Ginseng-based carbon dots inhibit the growth of squamous cancer cells by increasing ferroptosis.Frontiers in oncology · 2023Article
- Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
Immunotherapy revolutionized cancer treatment but has yet to elicit durable responses in the majority of patients with head and neck squamous cell carcinoma (HNSCC). HNSCC is generally characterized by a high tumor mutational burden, which has translated to a large neoantigen load that could prime the immune system to recognize and eliminate malignant cells. Studies are increasingly showing, however, that HNSCC is an "immune desert" tumor that can hijack multiple parts of the tumor immunity cycle in order to evade immune recognition and suppress immune system activation. Herein we will review how HNSCC tumors modulate their architecture, cellular composition, and cytokine milieu to maximize immunosuppression; as well as relevant therapeutic opportunities and emerging issues facing the field of HNSCC immuno-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.